Commodore Capital LP Aclaris Therapeutics, Inc. Transaction History

Commodore Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.07 - $17.95 $8.8 Million - $22.4 Million	-1,245,286 Reduced 66.23%	635,000 $5.14 Million
Q4 2022 Feb 14, 2023	SELL	$14.33 - $18.37 $7.6 Million - $9.74 Million	-530,336 Reduced 22.0%	1,880,286 $29.6 Million
Q2 2022 Aug 15, 2022	BUY	$10.16 - $17.08 $975,095 - $1.64 Million	95,974 Added 4.15%	2,410,622 $33.7 Million
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $3.48 Million - $6.41 Million	-357,698 Reduced 13.39%	2,314,648 $39.9 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $5.91 Million - $8.91 Million	482,055 Added 22.01%	2,672,346 $38.9 Million
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $6.98 Million - $9.8 Million	521,304 Added 31.23%	2,190,291 $39.4 Million
Q2 2021 Aug 16, 2021	BUY	$17.08 - $29.6 $10.9 Million - $19 Million	640,903 Added 62.34%	1,668,987 $29.3 Million
Q1 2021 May 17, 2021	SELL	$5.86 - $27.73 $1.81 Million - $8.55 Million	-308,191 Reduced 23.06%	1,028,084 $25.9 Million
Q4 2020 Feb 16, 2021	BUY	$2.65 - $7.61 $3.54 Million - $10.2 Million	1,336,275 New	1,336,275 $8.65 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $193M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.